Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights increased data management, DE&I, and ...

Cumberland Pharmaceuticals has reported positive outcomes from a trial of ifetroban as a potential treatment for Duchenne ...

Invivyd (IVVD) announced positive data from its ongoing Phase 1/2 clinical trial of VYD2311, Invivyd’s novel monoclonal antibody candidate ...

PhaseV has formed a strategic collaboration with Alimentiv for supporting the design and execution of adaptive clinical ...

Experts at the 2025 Clinical Trial Supply Europe conference will explore supply chain challenges and the impact of AI on ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy Peter Ronco, CEO, Emmes, discusses the number of ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial ...

Wave Life Sciences (NASDAQ:WVE) announced clinical trial application approval and initiation of the Phase 1 INLIGHT clinical ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new ...